Search details
1.
Advances in the Development of Therapeutics for Cytomegalovirus Infections.
J Infect Dis
; 221(Suppl 1): S32-S44, 2020 03 05.
Article
in English
| MEDLINE | ID: mdl-32134483
2.
Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
J Infect Dis
; 221(7): 1117-1126, 2020 03 16.
Article
in English
| MEDLINE | ID: mdl-31781762
3.
A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
Clin Infect Dis
; 70(8): 1525-1533, 2020 04 10.
Article
in English
| MEDLINE | ID: mdl-31179485
4.
Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.
Am J Transplant
; 20(6): 1703-1711, 2020 06.
Article
in English
| MEDLINE | ID: mdl-31883426
5.
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
N Engl J Med
; 377(25): 2433-2444, 2017 12 21.
Article
in English
| MEDLINE | ID: mdl-29211658
6.
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
Clin Infect Dis
; 60(12): 1842-51, 2015 06 15.
Article
in English
| MEDLINE | ID: mdl-25767256
7.
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Ann Intern Med
; 161(7): 461-71, 2014 Oct 07.
Article
in English
| MEDLINE | ID: mdl-25285539
8.
Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014.
J Pediatric Infect Dis Soc
; 12(12): 602-609, 2023 Dec 16.
Article
in English
| MEDLINE | ID: mdl-37815035
9.
A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
HIV Clin Trials
; 13(3): 119-30, 2012.
Article
in English
| MEDLINE | ID: mdl-22592092
10.
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.
HIV Clin Trials
; 13(4): 228-32, 2012.
Article
in English
| MEDLINE | ID: mdl-22849964
11.
Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients.
Clin Pharmacol Ther
; 111(2): 485-495, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34674258
12.
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Clin Infect Dis
; 53(8): 807-16, 2011 Oct.
Article
in English
| MEDLINE | ID: mdl-21921224
13.
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Lancet
; 375(9712): 396-407, 2010 Jan 30.
Article
in English
| MEDLINE | ID: mdl-20074791
14.
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Lancet
; 374(9692): 796-806, 2009 Sep 05.
Article
in English
| MEDLINE | ID: mdl-19647866
15.
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Clin Infect Dis
; 46(11): 1769-81, 2008 Jun 01.
Article
in English
| MEDLINE | ID: mdl-18433307
16.
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.
Open Forum Infect Dis
; 4(1): ofw047, 2017.
Article
in English
| MEDLINE | ID: mdl-28480227
17.
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
Lancet HIV
; 4(11): e486-e494, 2017 11.
Article
in English
| MEDLINE | ID: mdl-28918877
18.
Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.
Clin Infect Dis
; 37(8): 1119-24, 2003 Oct 15.
Article
in English
| MEDLINE | ID: mdl-14523778
19.
Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without Adjuvants.
Open Forum Infect Dis
; 1(1): ofu016, 2014 Mar.
Article
in English
| MEDLINE | ID: mdl-25734089
20.
Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.
PLoS One
; 9(3): e90485, 2014.
Article
in English
| MEDLINE | ID: mdl-24603872